This is a Notice of Intent, not a request for proposal. The National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health (NIH) intends to negotiate on an other than full and open competition basis with Discovery Life Sciences for the OLINK proteomic platform.

The National Institute of Allergy and Infectious Diseases (NIAID), requires the OLINK proteomic platform which will be used to explore immune system function as measured in serum proteins. This work will involve studies of COVID-19-recovered individuals, and as above, was previously used for a study of these and similar subjects. The OLINK platform measures 92 proteins per panel and uses the methodology based on the proximity extension assay to ensure it measures proteins with high specificity. The LISB is studying the systems biology of the immune system on a global scale, and at single cell resolution. Proteomic assays allow profiling of hundreds of proteins in parallel in body fluids. Many of these proteins reflect immune system function and allow unique insight into how the immune system operates in health and disease.

The LISB has previously used the OLINK proteomic platform the explore immune system function in COVID-19-recovered individuals. This project would be a continuation of that work, and for this reason, we want to continue to use the OLINK proteomic platform. The OLINK proteomic platform will be used to explore immune system function as measured in serum proteins. This work will involve studies of COVID-19-recovered individuals, and as above, was previously used for a study of these and similar subjects. The OLINK platform measures 92 proteins per panel and uses the methodology based on the proximity extension assay to ensure it measures proteins with high specificity.

The statutory authority for this sole source requirement is 41 U.S.C. 1901 (a) (1) as implemented by FAR 13.106-1 only one responsible source and no other supply of service will satisfy agency requirements. THIS IS NOT A REQUEST FOR PROPOSAL. All responsible sources that could provide comparable services may submit a capability statement that will be considered by email (subject line to reference NOI-NIAID-2175543 to Maliaka Pinkney at maliaka.pinkney@nih.gov, by 12:00 pm eastern standard time May 24, 2023. All responses received by the closing date of this synopsis will be considered by the Government. A determination not to compete this requirement, based upon responses to this notice, is solely within the discretion of the Government.

Attachments/Links